 Karen Moulton
Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atherosclerosis | 6 | 2023 | 402 | 1.030 |
Why?
| | Vascular Remodeling | 6 | 2022 | 192 | 1.020 |
Why?
| | Coronary Vessels | 2 | 2018 | 239 | 1.020 |
Why?
| | Heart-Assist Devices | 4 | 2022 | 538 | 1.000 |
Why?
| | PTEN Phosphohydrolase | 4 | 2020 | 159 | 0.940 |
Why?
| | Neovascularization, Pathologic | 4 | 2011 | 297 | 0.830 |
Why?
| | Fibrosis | 7 | 2023 | 526 | 0.790 |
Why?
| | Myocytes, Smooth Muscle | 6 | 2023 | 259 | 0.770 |
Why?
| | Plaque, Atherosclerotic | 3 | 2023 | 55 | 0.760 |
Why?
| | Myofibroblasts | 3 | 2023 | 121 | 0.400 |
Why?
| | Muscle, Smooth, Vascular | 6 | 2023 | 444 | 0.390 |
Why?
| | Aortic Diseases | 2 | 2021 | 114 | 0.370 |
Why?
| | Heart Failure | 3 | 2021 | 2148 | 0.360 |
Why?
| | Matrix Metalloproteinases | 1 | 2011 | 91 | 0.350 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2011 | 183 | 0.330 |
Why?
| | Hypercholesterolemia | 2 | 2023 | 102 | 0.300 |
Why?
| | Diabetic Nephropathies | 1 | 2011 | 284 | 0.290 |
Why?
| | Apolipoproteins E | 4 | 2009 | 77 | 0.280 |
Why?
| | Vasa Vasorum | 2 | 2004 | 37 | 0.270 |
Why?
| | Mice | 17 | 2023 | 16983 | 0.240 |
Why?
| | Arteriosclerosis | 2 | 2003 | 89 | 0.230 |
Why?
| | Collagen Type XVIII | 1 | 2004 | 4 | 0.230 |
Why?
| | Capillary Permeability | 1 | 2004 | 141 | 0.220 |
Why?
| | Receptors, LDL | 4 | 2023 | 47 | 0.200 |
Why?
| | Spinocerebellar Ataxias | 1 | 2022 | 6 | 0.200 |
Why?
| | Vascular System Injuries | 1 | 2023 | 73 | 0.190 |
Why?
| | Mice, Inbred C57BL | 9 | 2023 | 5468 | 0.190 |
Why?
| | Cell Differentiation | 6 | 2023 | 1900 | 0.190 |
Why?
| | Genes, X-Linked | 1 | 2022 | 17 | 0.190 |
Why?
| | X Chromosome Inactivation | 1 | 2022 | 23 | 0.190 |
Why?
| | Aortic Valve Insufficiency | 1 | 2022 | 46 | 0.190 |
Why?
| | Aortic Valve | 2 | 2022 | 348 | 0.190 |
Why?
| | Assisted Circulation | 1 | 2021 | 26 | 0.180 |
Why?
| | Animals | 18 | 2023 | 35409 | 0.180 |
Why?
| | DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2020 | 17 | 0.170 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2020 | 66 | 0.170 |
Why?
| | Actins | 2 | 2022 | 410 | 0.160 |
Why?
| | Peptide Fragments | 2 | 2003 | 695 | 0.160 |
Why?
| | Sesquiterpenes | 1 | 1999 | 53 | 0.150 |
Why?
| | Tunica Intima | 1 | 1999 | 84 | 0.150 |
Why?
| | High-Throughput Screening Assays | 1 | 2020 | 139 | 0.150 |
Why?
| | Mice, Knockout, ApoE | 1 | 2018 | 11 | 0.150 |
Why?
| | Macrophages | 3 | 2007 | 1489 | 0.150 |
Why?
| | Aorta, Thoracic | 2 | 2007 | 263 | 0.140 |
Why?
| | Mice, Knockout | 7 | 2016 | 2888 | 0.140 |
Why?
| | Endothelium, Vascular | 3 | 2018 | 902 | 0.140 |
Why?
| | Extracellular Matrix | 1 | 2021 | 508 | 0.140 |
Why?
| | Hyperplasia | 1 | 2018 | 175 | 0.140 |
Why?
| | Vascular Diseases | 1 | 2019 | 240 | 0.130 |
Why?
| | Collagen | 1 | 1999 | 438 | 0.130 |
Why?
| | Gene Expression | 1 | 2022 | 1465 | 0.130 |
Why?
| | Myocardial Ischemia | 1 | 2018 | 259 | 0.130 |
Why?
| | Serum Response Factor | 1 | 2016 | 32 | 0.130 |
Why?
| | Gene Expression Regulation | 3 | 2022 | 2545 | 0.130 |
Why?
| | Disease Models, Animal | 4 | 2022 | 4077 | 0.120 |
Why?
| | Heart | 2 | 2018 | 645 | 0.120 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2011 | 3630 | 0.110 |
Why?
| | Ventricular Function, Left | 1 | 2018 | 529 | 0.110 |
Why?
| | Male | 11 | 2023 | 63759 | 0.110 |
Why?
| | Stem Cells | 3 | 2023 | 578 | 0.110 |
Why?
| | Lymphatic Vessels | 1 | 2014 | 61 | 0.110 |
Why?
| | Mice, Transgenic | 5 | 2020 | 2135 | 0.100 |
Why?
| | Lipoproteins | 1 | 2014 | 172 | 0.100 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2004 | 528 | 0.100 |
Why?
| | Endostatins | 2 | 2004 | 10 | 0.100 |
Why?
| | Rats | 3 | 2019 | 5487 | 0.090 |
Why?
| | Female | 8 | 2023 | 68829 | 0.090 |
Why?
| | Immunohistochemistry | 3 | 2022 | 1690 | 0.080 |
Why?
| | Rats, Sprague-Dawley | 2 | 2016 | 2403 | 0.080 |
Why?
| | Cells, Cultured | 5 | 2022 | 4102 | 0.080 |
Why?
| | MAP Kinase Kinase Kinase 3 | 1 | 2009 | 4 | 0.080 |
Why?
| | Simvastatin | 1 | 2009 | 60 | 0.080 |
Why?
| | Middle Aged | 3 | 2021 | 31177 | 0.080 |
Why?
| | Aged | 2 | 2018 | 22107 | 0.080 |
Why?
| | Humans | 13 | 2023 | 129847 | 0.070 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2009 | 132 | 0.070 |
Why?
| | Profilins | 1 | 2007 | 3 | 0.070 |
Why?
| | Cholesterol | 2 | 2023 | 412 | 0.070 |
Why?
| | Vasculitis | 1 | 2007 | 65 | 0.070 |
Why?
| | Biomarkers | 2 | 2022 | 3971 | 0.060 |
Why?
| | Adult | 2 | 2018 | 35634 | 0.060 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 430 | 0.060 |
Why?
| | Angiotensin II | 2 | 2019 | 95 | 0.060 |
Why?
| | Diet, Atherogenic | 1 | 2004 | 6 | 0.060 |
Why?
| | Cholesterol, Dietary | 1 | 2004 | 18 | 0.060 |
Why?
| | In Vitro Techniques | 2 | 2004 | 1092 | 0.060 |
Why?
| | E-Selectin | 1 | 2004 | 55 | 0.060 |
Why?
| | Organ Culture Techniques | 1 | 2004 | 155 | 0.060 |
Why?
| | Corn Oil | 1 | 2023 | 5 | 0.050 |
Why?
| | Gene Dosage | 1 | 2004 | 143 | 0.050 |
Why?
| | Angiostatins | 1 | 2003 | 3 | 0.050 |
Why?
| | Proprotein Convertase 9 | 1 | 2023 | 68 | 0.050 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2003 | 78 | 0.050 |
Why?
| | Endothelial Growth Factors | 1 | 2003 | 63 | 0.050 |
Why?
| | Plasminogen | 1 | 2003 | 30 | 0.050 |
Why?
| | Lymphokines | 1 | 2003 | 127 | 0.050 |
Why?
| | Blotting, Western | 2 | 2019 | 1204 | 0.050 |
Why?
| | Muscle, Smooth | 1 | 2023 | 160 | 0.050 |
Why?
| | Chemokine CCL2 | 1 | 2003 | 117 | 0.050 |
Why?
| | Angiogenesis Inhibitors | 1 | 2004 | 218 | 0.050 |
Why?
| | Feedback | 1 | 2003 | 163 | 0.050 |
Why?
| | Neointima | 1 | 2022 | 15 | 0.050 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2023 | 158 | 0.050 |
Why?
| | Matrix Metalloproteinases, Secreted | 1 | 2021 | 12 | 0.050 |
Why?
| | Long Term Adverse Effects | 1 | 2021 | 12 | 0.050 |
Why?
| | ADAMTS4 Protein | 1 | 2021 | 16 | 0.050 |
Why?
| | DNA Helicases | 1 | 2023 | 146 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2003 | 373 | 0.050 |
Why?
| | Lipid Metabolism | 1 | 2004 | 503 | 0.040 |
Why?
| | Endothelial Cells | 2 | 2022 | 749 | 0.040 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2020 | 89 | 0.040 |
Why?
| | Monocytes | 1 | 2003 | 554 | 0.040 |
Why?
| | Skin | 1 | 2004 | 725 | 0.040 |
Why?
| | Chromatin | 1 | 2023 | 478 | 0.040 |
Why?
| | Swine | 1 | 2022 | 761 | 0.040 |
Why?
| | Cyclohexanes | 1 | 1999 | 21 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 426 | 0.040 |
Why?
| | Azacitidine | 1 | 2020 | 137 | 0.040 |
Why?
| | Wnt Signaling Pathway | 1 | 2020 | 170 | 0.040 |
Why?
| | Aortic Valve Stenosis | 1 | 2022 | 219 | 0.040 |
Why?
| | Arteries | 1 | 2020 | 266 | 0.040 |
Why?
| | Cell Count | 1 | 1999 | 318 | 0.040 |
Why?
| | Homeostasis | 1 | 2022 | 605 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2023 | 615 | 0.040 |
Why?
| | Nuclear Proteins | 1 | 2023 | 660 | 0.040 |
Why?
| | Promoter Regions, Genetic | 2 | 2020 | 1213 | 0.040 |
Why?
| | Cell Division | 1 | 1999 | 790 | 0.030 |
Why?
| | Sex Factors | 1 | 2022 | 1973 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1160 | 0.030 |
Why?
| | Transcriptome | 1 | 2022 | 875 | 0.030 |
Why?
| | Receptors, Lipoprotein | 1 | 1995 | 4 | 0.030 |
Why?
| | Foam Cells | 1 | 1995 | 15 | 0.030 |
Why?
| | Gene Targeting | 1 | 1995 | 81 | 0.030 |
Why?
| | Young Adult | 1 | 2011 | 12467 | 0.030 |
Why?
| | Transcription Factors | 1 | 2023 | 1645 | 0.030 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1995 | 88 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor Receptor-3 | 1 | 2014 | 7 | 0.030 |
Why?
| | Apolipoproteins B | 1 | 2014 | 43 | 0.030 |
Why?
| | Receptors, Immunologic | 1 | 1995 | 216 | 0.030 |
Why?
| | RNA | 1 | 2019 | 877 | 0.030 |
Why?
| | Signal Transduction | 2 | 2022 | 4935 | 0.030 |
Why?
| | Adolescent | 1 | 2011 | 20451 | 0.020 |
Why?
| | Inflammation | 1 | 2003 | 2748 | 0.020 |
Why?
| | Child | 1 | 2011 | 20962 | 0.020 |
Why?
| | Radio Waves | 1 | 1991 | 17 | 0.020 |
Why?
| | Atrioventricular Node | 1 | 1991 | 15 | 0.020 |
Why?
| | Electrodes | 1 | 1991 | 105 | 0.020 |
Why?
| | Lipids | 1 | 2014 | 628 | 0.020 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2009 | 56 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2009 | 124 | 0.020 |
Why?
| | Renin-Angiotensin System | 1 | 2009 | 82 | 0.020 |
Why?
| | Membrane Proteins | 1 | 1995 | 1119 | 0.020 |
Why?
| | Random Allocation | 1 | 2009 | 347 | 0.020 |
Why?
| | Benzamides | 1 | 2009 | 203 | 0.020 |
Why?
| | Time Factors | 1 | 1999 | 6550 | 0.020 |
Why?
| | Reference Values | 1 | 2009 | 796 | 0.020 |
Why?
| | Cardiac Catheterization | 1 | 1991 | 520 | 0.020 |
Why?
| | CD36 Antigens | 1 | 2007 | 36 | 0.020 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2007 | 37 | 0.020 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2007 | 171 | 0.020 |
Why?
| | Lipoproteins, LDL | 1 | 2007 | 127 | 0.020 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2007 | 203 | 0.020 |
Why?
| | Heterozygote | 1 | 2007 | 271 | 0.020 |
Why?
| | Cardiac Surgical Procedures | 1 | 1991 | 509 | 0.020 |
Why?
| | HL-60 Cells | 1 | 2004 | 33 | 0.010 |
Why?
| | Transduction, Genetic | 1 | 2004 | 124 | 0.010 |
Why?
| | Cornea | 1 | 2004 | 128 | 0.010 |
Why?
| | Neovascularization, Physiologic | 1 | 2004 | 176 | 0.010 |
Why?
| | Cell Adhesion | 1 | 2004 | 455 | 0.010 |
Why?
| | Leukocytes | 1 | 2004 | 306 | 0.010 |
Why?
| | Gene Deletion | 1 | 2004 | 380 | 0.010 |
Why?
| | Blood Pressure | 1 | 2009 | 1736 | 0.010 |
Why?
| | Aorta | 1 | 2004 | 408 | 0.010 |
Why?
| | Cell Movement | 1 | 2004 | 950 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2004 | 1847 | 0.010 |
Why?
| | Cytokines | 1 | 2004 | 2022 | 0.010 |
Why?
| | Scavenger Receptors, Class B | 1 | 1995 | 11 | 0.010 |
Why?
| | Receptors, Scavenger | 1 | 1995 | 21 | 0.010 |
Why?
| | Postoperative Period | 1 | 1991 | 330 | 0.010 |
Why?
| | Equipment Design | 1 | 1991 | 514 | 0.000 |
Why?
| | Myocardium | 1 | 1991 | 983 | 0.000 |
Why?
| | Follow-Up Studies | 1 | 1991 | 4896 | 0.000 |
Why?
|
|
Moulton's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|